A study of some new absolute summability methods

W. Sulaiman

DOI: https://doi.org/10.1155/S0161171297000379

Abstract:In this note we introduce a new method of absolute summability. A general theorem is given. Several results are also deduced.

What problem does this paper attempt to address?

Outcomes of Liver–kidney Transplantation in Patients with Primary Hyperoxaluria: an Analysis of the Scientific Registry of Transplant Recipients Database

Jie Xiang,Zheng Chen,Fangshen Xu,Shengmin Mei,Zhiwei Li,Jie Zhou,Yinlei Dong,Yangjun Gu,Zhichao Huang,Zhenhua Hu

DOI: https://doi.org/10.1186/s12876-020-01349-1

2020-01-01

BMC Gastroenterology

Abstract:Primary hyperoxaluria (PH) is an inherited disease lacking of hepatic oxalic acid metabolic enzymes which could lead to irreverisible renal damage. Currently, liver–kidney transplantation is a curative but highly invasive therapy used to treat patients with PH. However, limited studies have focused on combined liver–kidney transplantation (CLKT) and sequential liver and kidney transplantation (SLKT) in patients with PH. The present study included 201 patients with PH who received both liver and kidney transplants and who were listed on the Scientific Registry of Transplant Recipients from 1987 to 2018. According to the liver–kidney transplant procedure, patients were separated into a CLKT group and a SLKT group. Patient demographics and transplant outcomes were assessed in each group. Compared with the SLKT group, The CLKT group got a worse pretransplant dialysis condition in both the proportion of patients under pretransplant dialysis (p = 0.048) and the duration of the pretransplant dialysis (p < 0.001). The SLKT group got higher human leukocyte antigen mismatch score of kidney donor (p < 0.001) and liver donor (p = 0.003). The CLKT group utilized higher proportion (98.9%) of organs from a single deceased donor, while the SLKT group utilized 75.0% of organs from deceased liver donors and only 35.0% of organs from deceased kidney donors (p < 0.001). Kidney function measured by serum creatinine concentration before liver transplantation (LT) or CLKT was similar (p = 0.305) between groups. Patient survival was not significantly different between the two groups (p = 0.717) and liver (p = 0.685) and kidney (p = 0.464) graft outcomes were comparable between the two groups. SLKT seems to be an alternative option with strict condition for CLKT, further exploration about the SLKT is still required.
Survival Outcomes of Lung Transplant Recipients From Donors With Abnormal Kidney Function

Magdy M El-Sayed Ahmed,Sadia Z Shah,Nan Zhang,Tambi Jarmi,Samuel Jacob,Ian A Makey,Mathew Thomas,Basar Sareyyupoglu,Kevin P Landolfo,David B Erasmus,Si M Pham

DOI: https://doi.org/10.1016/j.athoracsur.2022.10.016

Abstract:Background: Recovering lungs with pulmonary edema due to abnormal kidney function is considered one of the expanded selection criteria for lung transplant. The aim of this study is to assess lung transplant recipients' survival from donors with abnormal kidney function and to determine differences in lung recovery rates from donors with and donors without abnormal kidney function. Methods: We reviewed the United Network for Organ Sharing registry for first-time adult lung transplant donors and recipients from June 2005 to March 2017. Donor kidney function was categorized into three groups based on estimated glomerular filtration rate: group I, greater than 60 mL/min; group II, 15 to 59 mL/min; and group III, less than 15 mL/min. Recipient survival was stratified based on estimated glomerular filtration rate using Kaplan-Meier. A multivariate Cox Regression model with known risk factors that affect survival was used to compare survival among groups. Comparison of lung recovery among the three groups was also performed. Results: Lung recovery rates were 29.7% (15,670 of 52,747), 19.4% (3879 of 20,040), and 18.1% (704 of 3898) for groups I, II, and III, respectively. The 1-, 3-, and 5-year recipient survival rates were 86.2%, 69.2%, and 55.7% for group I; 84.9%, 66.9%, and 53.8% for group II; and 85.5%, 65.3%, and 50.3% for group III, respectively (adjusted P = .25; multivariate Cox regression method). When group I was used as reference, the adjusted hazard ratio for group II was 1.04 (95% CI, 0.98-1.10) and for group III, it was 1.08 (95% CI, 0.96-1.23), after adjusting with the multivariate Cox regression model. Conclusions: There was no significant difference in lung recipient survival. The lung recovery rate from donors with abnormal kidney function was lower compared with that of donors with normal kidney function.
Renal Outcomes After Simultaneous Liver‐Kidney Transplantation: Results from the US Multicenter Simultaneous Liver‐Kidney Transplantation Consortium

Pratima Sharma,Zhiyu Sui,Min Zhang,John C. Magee,Pranab Barman,Yuval Patel,Aaron Schluger,Kara Walter,Scott W. Biggins,Giuseppe Cullaro,Randi Wong,Jennifer C. Lai,Jennifer Jo,Jasmine Sinha,Lisa VanWagner,Elizabeth C. Verna

DOI: https://doi.org/10.1002/lt.26032

2021-04-21

Liver Transplantation

Abstract:SLKT is increasingly common in the United States (US). However, little is known about the renal‐related outcomes following SLKT, which will be essential to maximize the health of these allografts. We examined the factors impacting renal function following simultaneous liver‐kidney transplant (SLKT). MethodsThis is an observational multicenter cohort study from the US Multicenter SLKT consortium consisting of recipients of SLKT aged ≥18 years performed between 2/2002‐6/2017 at six large US centers in six different United Network for Organ Sharing regions(UNOS). The primary outcome was incident post‐SLKT stage4‐5 chronic kidney disease(CKD) defined as <30ml/min/1.73m2 or listing for kidney transplant. ResultsThe median age (N=570) was 58 years(interquartile‐range:51‐64), 37% were female, 76% were white, 33% had hepatitis C, 20% had nonalcoholic steatohepatitis (NASH), and 23% had alcohol‐associated liver disease; 68% developed ≥stage3 CKD at the end of follow up. The 1‐, 3‐ and 5‐ year incidence of post‐SLKT stage4‐5 CKD was 10%, 12%, and 16%. Pre‐SLKT diabetes (HR=1.45[1.00‐2.15]), NASH(HR=1.58[1.01‐2.45]), and delayed kidney graft function(HR=1.72[1.10‐2.71]) were the recipient factors independently associated with high risk, whereas use of tacrolimus (HR=0.44[0.22‐0.89]) reduced the risk. Females (β=‐6.22±2.16ml/min/1.73 m2; P=0.004), NASH (β=‐7.27±3.27ml/min/1.73 m2;p=0.027) and delayed kidney graft function (β=‐7.25± 2.26ml/min/1.73 m2;P=0.007) were independently associated with low eGFR at last follow‐up. ConclusionsStage4‐5 CKD is common after SLKT. There remains an unmet need for personalized renal protective strategies, specifically stratified by sex, diabetes, and liver disease, to preserve renal function among SLKT recipients.

gastroenterology & hepatology,surgery,transplantation
Kidney After Lung Transplants or Combined Kidney-Lung Transplantation: A Single-Center Retrospective Cohort Study

Benoît Mesnard,Matthieu Glorion,Arwa Jalal Eddine,Antoine Roux,Julien Branchereau,Yann Neuzillet,Edouard Sage,Thierry Lebret,Alexandre Hertig,François-Xavier Madec,Yanish Soorojebally

DOI: https://doi.org/10.12659/AOT.944049

2024-08-13

Abstract:BACKGROUND End-stage renal disease is a major issue in the management of patients undergoing lung transplantation. Combined kidney-lung transplantation (CKLT) and kidney after lung transplantation (KALT) are the 2 preferred solutions to manage this situation. To evaluate these strategies, we describe kidney and lung graft outcomes and patient survival in patients managed with CKLT and KALT. MATERIAL AND METHODS We conducted a retrospective single-center cohort study. Patients who underwent a CKLT or a KALT were included in this study. Retrospective extraction of data from medical records was performed. RESULTS Seventeen patients underwent CKLT and 9 underwent KALT. Most of the patients had cystic fibrosis and presented renal failure related to anti-calcineurin toxicity. The 30-day and 1-year survival of CKLT recipients were both 75.6%. No patients with KALT died during the follow-up. Kidney graft prognosis was almost exclusively influenced by patient survival in relation to postoperative lung transplant complications. The rate of severe surgical complications was close to 60% for CKLT compared with 30% for KALT. The kidney graft function (estimated kidney graft function) did not differ according to the transplantation strategy. CONCLUSIONS KALT is a safe option, with postoperative morbidity and renal graft function identical to those of kidney transplantation in non-lung-transplanted patients. The results of CKLT depend mainly on the morbidity associated with lung transplantation but remain an attractive option for patients with respiratory failure associated with end-stage renal disease. The choice of transplant strategy must also take into account the most ethical and efficient allocation of kidney grafts.
Temporal Trends and Evolving Outcomes After Simultaneous Liver‐Kidney Transplantation: Results from the US SLKT Consortium

Giuseppe Cullaro,Pratima Sharma,Jennifer Jo,Jasmine Rassiwala,Lisa B. VanWagner,Randi Wong,Jennifer C. Lai,John Magee,Aaron Schluger,Pranab Barman,Yuval A. Patel,Kara Walter,Scott W. Biggins,Elizabeth C. Verna

DOI: https://doi.org/10.1002/lt.26232

2021-08-20

Liver Transplantation

Abstract:We aimed to understand the contemporary changes in the characteristics and the determinants of outcomes among SLKT recipients at six liver transplant centers in the US. We retrospectively enrolled SLKT recipients between 2002–2017 in the US Multicenter SLKT Consortium. We analyzed time-related trends in recipient characteristics and outcomes with linear regression and non-parametric methods. Clustered cox-regression determined the factors associated with 1-year and overall survival. We enrolled 572 patients. We found significant changes in the clinical characteristics of SLKT recipients: as compared to 2002, recipients in 2017 were older (59v.52 years, p<0.001) and more likely to have CKD (71%v.33%,p<0.001). There was a marked improvement in 1-year survival during the study period: 89% in 2002 v. 96% in 2017 (p<0.001). We found that the drivers of 1-year mortality were SLKT year, hemodialysis at listing, donor distance, and delayed kidney allograft function. The drivers of overall mortality were an indication of AKD, BMI, hypertension, creatinine at SLKT, ventilation at SLKT, and donor quality. In this contemporary cohort of SLKT recipients, we highlight changes in the clinical characteristics of recipients. Further, we identify the determinants of 1-year and overall survival to highlight the variables that require the greatest attention to optimize outcomes.

gastroenterology & hepatology,surgery,transplantation
Outcomes of Simultaneous Liver‐Kidney Transplantation Using Kidneys of Deceased Donors With Acute Kidney Injury

Ramesh K. Batra,Venkatesh K. Ariyamuthu,Malcolm P. MacConmara,Gaurav Gupta,Ahmet B. Gungor,Bekir Tanriover

DOI: https://doi.org/10.1002/lt.26406

2022-03-03

Liver Transplantation

Abstract:Outcomes from simultaneous liver-kidney transplantation (SLKT) when using kidneys from donors with acute kidney injury (AKI) have not been studied. We studied 5344 SLKTs between May 1, 2007, and December 31, 2019, by using Organ Procurement and Transplantation Network registry data supplemented with United Network for Organ Sharing-DonorNet data. Designating a donor as having AKI required by definition that the following criteria were met: (1) the donor's condition aligned with the Kidney Disease: Improving Global Outcomes (KDIGO) international consensus guidelines and the terminal serum creatinine (Scr) level was ≥1.5 times the minimum Scr level for deceased donors before organ recovery and (2) the terminal Scr level was ≥1.5 mg/dL (a clinically meaningful and intuitive Scr threshold for defining AKI for transplant providers). The primary outcomes were liver transplant all-cause graft failure (ACGF; defined as graft failures and deaths) and kidney transplant death-censored graft failure (DCGF) at 1 year after transplant. The donors with AKI were young, had good organ quality, and had a short cold ischemia time. In the study cohort, 4482 donors had no AKI, whereas 862 had AKI (KDIGO AKI stages: 1, n = 521; 2, n = 202; and 3, n = 138). In the group with AKI and the group with no AKI, respectively, liver ACGF at 1 year (11.1% versus 12.9% [P = 0.13]; hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.97-1.49) and kidney DCGF at 1 year (4.6% versus 5.7% [P = 0.18]; HR, 1.27; 95% CI, 0.95-1.70) did not differ in the full multivariable Cox proportional hazard models. Selected kidneys from deceased donors with AKI can be considered for SLKT.

gastroenterology & hepatology,surgery,transplantation
The Prevalence, Risk Factors, and Prognosis of Acute Kidney Injury After Lung Transplantation: A Single-Center Cohort Study in China

Ling Sang,Sibei Chen,Lingbo Nong,Yonghao Xu,Wenhua Liang,Haichong Zheng,Liang Zhou,Huadong Sun,Jianxing He,Xiaoqing Liu,Yimin Li

DOI: https://doi.org/10.1016/j.transproceed.2020.10.031

Abstract:Purpose: The aim of this study is to evaluate the incidence, risk factors, and prognosis of acute kidney injury (AKI) after lung transplantation (LTx). Methods: Records of patients who underwent LTx in a single center were retrospectively reviewed. The prevalence of post-transplant AKI, the use of continuous renal replacement therapy (CRRT), and the risk factors for AKI were investigated. The effects of AKI and CRRT on short-term outcomes and long-term survival were measured. Results: This study included 148 patients, 67 of which developed postoperative AKI. Of these, 31 patients underwent CRRT; the percentage of cases with no AKI was 6.2%, and the percentage of cases with stage 1, 2, and 3 who used CRRT was 0%, 10%, and 86.2%, respectively. Patients with AKI had significantly higher intensive care unit mortality and in-hospital mortality. The 1-year post-LTx survival rate of patients with AKI was 47.8%, significantly lower than those without AKI (74.1%). There was no difference in 1-year survival rate of those with stage 1 and stage 2 AKI, but patients with stage 3 AKI showed the worst survival. Patients who underwent CRRT had an inferior survival outcome (9.7% vs 76.1%, P < .05). We found that higher acute physiologic assessment and chronic health evaluation (APACHE) II scores (odds ratio [OR] 1.082, P = .009) and higher intraoperative fluid balance (OR 1.001, P = .012) were independent risk factors, and female sex (OR 2.539) and pulmonary hypertension (OR 2.869) were potential risk factors for post-LTx AKI. A prediction model integration of the above factors showed a good concordance with actual risks and had a concordance index (C-index) of 0.76 (95% confidence interval [CI], 0.66-0.87). Conclusion: Severe AKI requiring CRRT had a negative impact on the short-term and long-term outcomes of patients.
Lung transplantation in HIV seropositive recipients: An analysis of the UNOS registry

Jack K. Donohue,Ernest G. Chan,Sarah Clifford,John P. Ryan,Masashi Furukawa,Ghady Haidar,Alessandro Bertani,Chadi A. Hage,Pablo G. Sanchez

DOI: https://doi.org/10.1111/ctr.15246

2024-01-25

Clinical Transplantation

Abstract:Background Experience with lung transplantation (LT) in patients with human immunodeficiency virus (HIV) is limited. Many studies have demonstrated the success of kidney and liver transplantation in HIV‐seropositive (HIV+) patients. Our objective was to conduct a national registry analysis comparing LT outcomes in HIV+ to HIV‐seronegative (HIV−) recipients. Methods The United Network for Organ Sharing database was queried to identify LTs performed in adult HIV+ patients between 2016 and 2023. Patients with unknown HIV status, multiorgan transplants, and redo transplants were excluded. The primary endpoints were mortality and graft rejection. Survival time was analyzed using Kaplan–Meier analysis. Results The study included 17 487 patients, 67 of whom were HIV+. HIV+ recipients were younger (59 vs. 62 years, p = .02), had higher pulmonary arterial pressure (28 vs. 25 mm Hg, p = .04), and higher lung allocation scores (47 vs. 41, p = .01) relative to HIV− recipients. There were no differences in graft/recipient survival time between groups. HIV+ recipients had higher rates of post‐transplant dialysis (18% vs. 8.4%, p = .01), but otherwise had similar post‐transplant outcomes to HIV‐recipients. Conclusions This national registry analysis suggests LT outcomes in HIV+ patients are not inferior to outcomes in HIV− patients and that well‐selected HIV+ recipients can achieve comparable patient and graft survival rates relative to HIV− recipients.

surgery,transplantation
Extended Recipient Criteria in Lung Transplantation: Impact of Pleural Abnormalities on Primary Graft Dysfunction

Simona Soresi,Mohamed Zeriouh,Anton Sabashnikov,Zubair Sarang,Prashant N Mohite,Nikhil P Patil,Ashham Mansur,Alexander Weymann,Jens Wippermann,Thorsten Wahlers,Anna Reed,Martin Carby,André R Simon,Aron-Frederik Popov

DOI: https://doi.org/10.1016/j.athoracsur.2015.11.068

Abstract:Background: Because of improved surgical expertise and intraoperative management, pleural disease (PD+) represents a relatively minor contraindication to lung transplantation (LTx). The presence of pleural abnormalities from previous procedures or pleural involvement from fungal or bacterial disease is not considered a limiting factor for LTx. However there are no studies available to assess the impact of pleural diseases on short- and midterm outcomes after LTx. Methods: We retrospectively reviewed 163 consecutive patients who underwent LTx between 2010 and 2013. Patients were divided according to the presence of pleural abnormalities before the operation (PD+ versus PD-). The primary end point of the study was primary graft dysfunction (PGD; grade 3) and overall survival. To avoid possible selection bias and to heck the robustness of the results, a propensity score-matching analysis (1:3) was performed. Results: A total of 26 patients (16%) had pleural abnormalities before transplantation. Intra- and postoperative variables were comparable. PD+ was associated with a significantly higher incidence of PGD at 0 and 48 hours postoperatively (p = 0.037 and p = 0.032, respectively). Moreover, PD+ was associated with significantly worse survival at 3 months (p = 0.021). Although there was a trend toward worse early overall survival in the Kaplan-Meier estimate (Breslow p = 0.050), midterm survival was comparable (log-rank p = 0.240). Conclusions: LTx in patients with preoperative pleural abnormalities is feasible. Identifying higher-risk recipients with pleural abnormalities might have important clinical relevance because of a higher incidence of PGD and worse early survival, even though midterm survival is comparable.
Kidney Transplantation as a Treatment Option of Chronic Renal Failure Among Lung Transplant Recipients: A Single-Center Experience

Marek Ochman,Fryderyk Zawadzki,Dagmara Galle,Anna Kowal,Magdalena Królikowska,Jawad Salman,Tomasz Hrapkowicz

DOI: https://doi.org/10.1016/j.transproceed.2024.02.006

IF: 1.014

2024-04-07

Transplantation Proceedings

Abstract:Introduction Chronic renal failure is one of the most common complications after solid organ transplantation. It is associated with multiple pre-, peri-, and post-transplant factors. In some patients, the available methods of conservative treatment are insufficient and kidney transplantation (KTx) is necessary. The aim of this study was to present our experience in the treatment of renal failure by KTx after lung transplantation (LTx). Methods Our study is a single-center retrospective review of clinical data of all 7 LTx recipients who underwent a KTx between the years 2013 and 2021. Patients' clinical condition, pulmonary function, renal function, and survival were examined. Results There were a total of 7 patients with medium age 36 years (±15). In 3 patients, the period of time from LTx to KTx was less than 3 years, and in 4 of them less than 13 years. Dialysis therapy was required in 4 patients. One patient had pre-LTx renal disease, while 6 patients had renal dysfunction related to post-transplant factors, including the use of calcineurin inhibitors. Conclusions Renal protection is a very important aspect among LTx recipients; therefore, physicians must show a holistic and individual approach to patients and minimize exposure to nephrotoxic medication. Patients at high risk of developing chronic renal failure should be identified and, if required, renal replacement therapy should be initiated, including KTx.

immunology,surgery,transplantation
Single vs Double Lung Transplantation in Older Adults: A Propensity-Matched Analysis

Noah Weingarten,Atul C Mehta,Marie Budev,Usman Ahmad,James Yun,Kenneth McCurry,Haytham Elgharably

DOI: https://doi.org/10.1016/j.chest.2024.08.044

IF: 9.6

2024-09-05

Chest

Abstract:Background: Single lung transplantation (SLT) is associated with worse long-term outcomes than bilateral lung transplantation (BLT), but often is performed in older adults at risk of not tolerating BLT. Research question: How do the outcomes of SLT and BLT compare among older adult recipients? Study design and methods: The Scientific Registry of Transplant Recipients database (2005-2022) was queried for lung transplant recipients 65 years of age or older. Patients were stratified by whether they underwent BLT or SLT and were propensity matched. Baseline characteristics and morbidity were compared with frequentist statistics. Survival was analyzed via Kaplan-Meier estimation. Risk factors for mortality were identified with Cox regression. Results: Of 9,904 included patients, 4,829 patients (48.8%) underwent SLT. Patients who underwent SLT had lower lung allocation scores (39.6 vs 40.6; P < .001), more interstitial lung disease (74.4% vs 64.6%; P < .001), and lower rates of bridging (0.7% vs 2.4%; P < .001). Groups did not differ significantly by sex, BMI, or donor characteristics. Propensity matching resulted in 2,539 patients in each group. On matched analysis, patients undergoing SLT had shorter lengths of stay (14 days vs 18 day), lower reintubation rates (14.7% vs 19.8%), and less postoperative dialysis use (4.2% vs 6.4%; P < .001 for all). Patients who underwent SLT had comparable survival at 30 days (97.6% vs 97.3%; P = .414) and 1 year (85.5% vs 86.3%; P = .496), but lower survival at 5 years (45.4% vs 53.4%; P < .001) on matched analysis. SLT was a risk factor for 5-year mortality (adjusted hazard ratio, 1.19; P < .001). Interpretation: In older adults, SLT is associated with less morbidity and comparable early survival relative to BLT, but lower 5-year survival. SLT is reasonable to perform in older adults at high risk of not tolerating BLT.
Performance status at the time of lung retransplant predicts long‐term function

Rachel L. Deitz,Sarah Clifford,John P. Ryan,Ernest G. Chan,Jenalee N. Coster,Masashi Furukawa,Chadi A. Hage,Pablo G. Sanchez

DOI: https://doi.org/10.1111/ctr.15310

2024-04-11

Clinical Transplantation

Abstract:Background Lung retransplantation is offered to select patients with chronic allograft dysfunction. Given the increased risk of morbidity and mortality conferred by retransplantation, post‐transplant function should be considered in the decision of who and when to list. The aim of this study is to identify predictors of post‐operative disability in patients undergoing lung retransplantation. Methods Data were collected from the UNOS national dataset and included all patients who underwent lung retransplant from May 2005–March 2023. Pre‐ and post‐operative function was reported by the Karnofsky Performance Status (KPS) and patients were stratified based on their needs. Cumulative link mixed effects models identified associations between pre‐transplant variables and post‐transplant function. Results A total of 1275 lung retransplant patients were included. After adjusting for between‐group differences, pre‐operative functional status was predictive of post‐transplant function; patients requiring Total Assistance ( n = 740) were 74% more likely than No/Some Assistance patients (n = 535) to require more assistance in follow‐up (OR 1.74, 95% CI 1.13–2.68, p = .012). Estimated one year survival of Total Assistance patients is lower than No/Some Assistance Recipients (72% vs. 82%, CI 69%–75%; 79%–86%) but similar to overall re‐transplant survival (76%, CI 74%–79%). Conclusion Both survival and regain of function in patients requiring Total Assistance prior to retransplant may be higher than previously reported. Pre‐operative functional status is predictive of post‐operative function and should weigh in the selection, timing and post‐operative care of patients considered for lung retransplantation.

surgery,transplantation
Lung Transplantation In China Between 2015 And 2018

Chun-Xiao Hu,Wen-Hui Chen,Jian-Xing He,Ge-Ning Jiang,Xiao-Shan Li,Dong Wei,Bo Wu,Ji Zhang,Chen Wang,Jing-Yu Chen

DOI: https://doi.org/10.1097/CM9.0000000000000543

IF: 6.133

2019-01-01

Chinese Medical Journal

Abstract:Background:Lung transplantation (LT) has been demonstrated as the only effective therapy for patients with end-stage lung diseases. Increasing listed lung transplant candidates and expanding volumes of lung transplant centers across China require well-organized programs and registry data collection based on the large population. This study aimed to summarize and analyze the data of LT development in China.Methods:We retrospectively collected and analyzed data from the China Lung Transplantation Registry (CLuTR). Key data were reported from the registry with transplant types, indications, donor and recipient characteristics, outcomes and survival. The survival <30 days, 1-year and 3-year survival rates were estimated with risk factors identified.Results:CLuTR contained data from 1053 lung transplants performed through January 1st, 2015 to December 31st, 2018 reported by 18 registered transplant centers. The largest category of diagnosis before transplantation was idiopathic interstitial pneumonitis. The total 30 days, 1-year and 3-year survival rates in CLuTR were 81.45%, 70.11%, and 61.16% with discrepancy by indications. Large proportion of recipients who were more than 60 years old required higher standard of care. Infection-related complications resulted in more death events in the early post-surgery periods. New York Heart Association grading at listing, extra-corporeal membrane oxygenation usage peri-transplantation, allograft dysfunction (primary graft dysfunction >Grade 0), renal insufficiency (estimated glomerular filtration rate <60 mLmin(-1)1.73 m(-2)), were independently associated with a higher risk for 3-year mortality in the entire cohort.Conclusions:Facing more end-stage of lung diseases and comorbidities, this study analyzed the outcomes and survival of LT recipients in China. Further prospectively stratified analyses with longer follow-up will be needed.
Motion synchronization for multi-cylinder electro-hydraulic system

Hong Sun,G.T.-C. Chiu

DOI: https://doi.org/10.1109/AIM.2001.936541

2001-07-08

Abstract:This paper presents a nonlinear control algorithm to address the motion synchronization problem for a 2-cylinder electrohydraulic (EH) system. A 2-step design approach is applied such that it utilized linear MIMO robust control technique to design an outer loop motion synchronization controller. A nonlinear SISO perturbation observer based pressure/force controller is designed for each of the lift cylinder as the inner loop controller to handle the nonlinearities associated with the EH actuators. Experimental results on a 2-cylinder system are presented to verify the effectiveness of the proposed approach.
Outcomes Following Lung Transplant for COVID-19-Related Complications in the US

Panagiotis Tasoudis,Leonard J Lobo,Raymond D Coakley,Chris B Agala,Thomas M Egan,Benjamin E Haithcock,Gita N Mody,Jason M Long

DOI: https://doi.org/10.1001/jamasurg.2023.3489

2023-11-01

Abstract:Importance: The COVID-19 pandemic led to the use of lung transplant as a lifesaving therapy for patients with irreversible lung injury. Limited information is currently available regarding the outcomes associated with this treatment modality. Objective: To describe the outcomes following lung transplant for COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis. Design, setting, and participants: In this cohort study, lung transplant recipient and donor characteristics and outcomes following lung transplant for COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis were extracted from the US United Network for Organ Sharing database from March 2020 to August 2022 with a median (IQR) follow-up period of 186 (64-359) days in the acute respiratory distress syndrome group and 181 (40-350) days in the pulmonary fibrosis group. Overall survival was calculated using the Kaplan-Meier method. Cox proportional regression models were used to examine the association of certain variables with overall survival. Exposures: Lung transplant following COVID-19-related acute respiratory distress syndrome or pulmonary fibrosis. Main outcomes and measures: Overall survival and graft failure rates. Results: Among 385 included patients undergoing lung transplant, 195 had COVID-19-related acute respiratory distress syndrome (142 male [72.8%]; median [IQR] age, 46 [38-54] years; median [IQR] allocation score, 88.3 [80.5-91.1]) and 190 had COVID-19-related pulmonary fibrosis (150 male [78.9%]; median [IQR] age, 54 [45-62]; median [IQR] allocation score, 78.5 [47.7-88.3]). There were 16 instances of acute rejection (8.7%) in the acute respiratory distress syndrome group and 15 (8.6%) in the pulmonary fibrosis group. The 1-, 6-, and 12- month overall survival rates were 0.99 (95% CI, 0.96-0.99), 0.95 (95% CI, 0.91-0.98), and 0.88 (95% CI, 0.80-0.94) for the acute respiratory distress syndrome cohort and 0.96 (95% CI, 0.92-0.98), 0.92 (95% CI, 0.86-0.96), and 0.84 (95% CI, 0.74-0.90) for the pulmonary fibrosis cohort. Freedom from graft failure rates were 0.98 (95% CI, 0.96-0.99), 0.95 (95% CI, 0.90-0.97), and 0.88 (95% CI, 0.79-0.93) in the 1-, 6-, and 12-month follow-up periods in the acute respiratory distress cohort and 0.96 (95% CI, 0.92-0.98), 0.93 (95% CI, 0.87-0.96), and 0.85 (95% CI, 0.74-0.91) in the pulmonary fibrosis cohort, respectively. Receiving a graft from a donor with a heavy and prolonged history of smoking was associated with worse overall survival in the acute respiratory distress syndrome cohort, whereas the characteristics associated with worse overall survival in the pulmonary fibrosis cohort included female recipient, male donor, and high recipient body mass index. Conclusions and relevance: In this study, outcomes following lung transplant were similar in patients with irreversible respiratory failure due to COVID-19 and those with other pretransplant etiologies.
Outcomes of single vs double lung retransplantation in patients with cystic fibrosis

Emily L Larson,Albert Leng,Jessica M Ruck,Alfred J Casillan,Alice L Zhou,Jinny S Ha,Pali D Shah,Natalie E West,Christian A Merlo,Errol L Bush

DOI: https://doi.org/10.1016/j.healun.2024.09.010

2024-09-18

Abstract:Background: Patients requiring lung transplant for cystic fibrosis (CF) may require retransplant due to limited graft survival and otherwise excellent life expectancy. Optimal transplant strategy for this population, including single vs double lung retransplant, has not been established. Methods: We performed a retrospective analysis of the United Network for Organ Sharing/Organ Procurement and Transplant Network (UNOS/OPTN) database to identify adult lung retransplant recipients from 2005 to 2021 with a primary diagnosis of CF. Patients were stratified by retransplant type (single lung [re-SLTx] vs double lung [re-DLTx] retransplant). Descriptive statistics, Kaplan-Meier survival analysis, and multivariable Cox regression were performed. Results: From 2005 to 2021, 384 recipients underwent retransplant after an initial transplant for an indication of CF; more recipients underwent re-DLTx (N = 337 [87.8%]) than re-SLTx (N = 47 [12.2%]). The median (IQR) time from initial transplant to retransplant was similar between re-SLTx and re-DLTx recipients (4.4 [2.9-8.6] vs 4.6 [2.6-7.4] years, p = 0.73). Ischemic time was shorter and lung allocation score was lower for re-SLTx than re-DLTx recipients. Median survival after retransplant was significantly shorter for re-SLTx vs re-DLTx recipients (2.0 [95% CI 1.2-3.5] vs 4.3 [95% CI 3.5-6.1] years post-retransplant, p = 0.008). Median survival for adults with CF undergoing primary transplant for CF in the same period was 9.1 (8.5-9.9) years. After adjusting for donor and recipient characteristics, re-SLTx in patients with CF was associated with 88% higher hazard of mortality than re-DLTx (aHR=1.88 [95% CI 1.28-2.78], p = 0.001). Conclusions: In this analysis of lung retransplant in recipients with CF, re-SLTx was associated with a higher hazard of mortality compared to re-DLTx, supporting re-DLTx as treatment for this population.
Longevity Matching for Living Donor Renal Transplantation

Jack Dawes,Andrew Gregor,Jonathan Kolansky,Kathleen Wirshup,Antonio Di Carlo,Sunil Karhadkar

DOI: https://doi.org/10.1016/j.transproceed.2023.11.026

IF: 1.014

2024-01-10

Transplantation Proceedings

Abstract:Introduction This study identifies the effect of individual donor and recipient characteristics on graft survival in living-donor kidney transplantation (LDKT) using a recently described novel measure, kidney life years (KLYs). Materials and Methods The Organ Procurement and Transplantation Network/United Network for Organ Sharing database was used to identify first-time kidney-only LDKT recipients between 1987 and 2020 who did not experience death with a functioning graft (DWFG) and were not missing relevant information (n = 87,290). Patient characteristics were evaluated using Cox and multiple regression analyses, with the dependent variable being KLYs. An equation for expected KLYs based on patient characteristics was created using regression coefficients. The equation was validated using bootstrapped Pearson correlations and then applied to the DWFG group for comparison. Results Based on statistical significance from Cox and multiple linear regression analyses, 9 of the original 18 variables were selected for inclusion in the equation. Variables with notable impact included HLA match points (0.021 KLYs; 95% CI: [0.019,0.024]; P ≤ .001), Donor Age (-0.030 KLYs; 95% CI: [-0.035,-0.025]; P ≤ .001), and Donor African American Ethnicity (-2.356 KLYs; 95% CI: [-2.552,-2.159]; P ≤ .001). Equation validation was supported, given a negative correlation (r = -0.071; P ≤ .001) between expected KLY change and observed graft failure. Expected KLY change was found to be greater in those who eventually DWFG when compared with all other LDKTs (t = -5.735, P ≤ .001). Conclusions Increasing HLA match points may be more beneficial for graft longevity than minimizing donor age in comparisons using realistic between-donor differences. Additionally, greater average expected KLYs in those who ultimately DWFG may illustrate an opportunity for improved donor-recipient matching.

immunology,surgery,transplantation
Post Liver Transplant Renal Dysfunction-Evaluation, Management and Immunosuppressive Practice

Kaiser Raja,Charles Panackel

DOI: https://doi.org/10.1016/j.jceh.2023.101306

Abstract:Liver transplantation (LT) is an effective and lifesaving treatment for patients with end-stage liver disease and hepatocellular carcinoma. Significant improvement in intermediate and long-term survival has been possible due to advancements in immunosuppressive therapy, perioperative care, and surgical techniques. Despite these advances, metabolic complications, including diabetes mellitus, cardiovascular diseases, malignancies, and renal dysfunction, are challenging issues after LT. Acute kidney injury (AKI) and chronic kidney disease (CKD) after LT are common and result in significant morbidity and mortality. Early diagnosis of kidney injury after LT is challenging, and no technique has yet proven effective in prediction of renal dysfunction. The methods for assessing renal function range from formulas that predict glomerular filtration rate to non-invasive biomarkers. The universal adoption of the model for end-stage liver disease has a direct impact on the incidence of peri-transplant AKI and development of CKD in the long-term. Post-LT renal dysfunction is multifactorial and is usually a result of pre-transplantation comorbidities, occurrence of renal dysfunction on the waiting list, perioperative events, and post-transplant nephrotoxic immunosuppressive medication use. Early identification of patients at risk for renal dysfunction and adoption of preventive measures are crucial in the pre-transplant period. No data are currently available to suggest a surgical technique that reliably demonstrates renal protection. Nephroprotective strategies during LT follow accepted surgical practice guidelines, such as maintenance of intravascular volume and mean arterial pressure. The management of kidney disease following LT is challenging, as by the time the serum creatinine is significantly elevated, few interventions impact the course of progression. Early nephroprotective measures are strongly advised and they mostly center on delaying the administration of calcineurin inhibitors (CNIs) during the initial postoperative period, lowering CNI dosage and combining CNI with mycophenolate mofetil and everolimus. The reasons for renal failure following LT, the techniques used to diagnose it, and the therapies designed to preserve renal function both immediately and late after LT are all critically evaluated in this review.
Impact of Postoperative Continuous Renal Replacement Therapy in Lung Transplant Recipients

Masato Katahira,Takashi Hirama,Shunsuke Eba,Takaya Suzuki,Hirotsugu Notsuda,Hisashi Oishi,Yasushi Matsuda,Tetsu Sado,Masafumi Noda,Akira Sakurada,Aman Sidhu,Yoshinori Okada

DOI: https://doi.org/10.1097/TXD.0000000000001013

2020-05-28

Abstract:Acute kidney injury (AKI) is a common complication after lung transplant (LTx), and continuous renal replacement therapy (CRRT) is increasingly of use to critically ill patients who have developed AKI. However, the optimal timing or threshold of kidney impairment for which to commence CRRT after LTx has been uncertain. There has also been limited information on the impact of CRRT among LTx recipients (LTRs) introduced in the early posttransplant period on survival, graft function, and renal function. We aimed to review LTRs who developed AKI requiring CRRT postoperatively and followed their long-term outcomes at Tohoku University Hospital (TUH). Methods: Medical records of consecutive patients who underwent LTx at TUH between 2000 and 2018 were reviewed, with follow-up to 2019 inclusive. Results: Although mortality in those who required CRRT (n = 21) was increased versus those who did not require CRRT (n = 85)(P = 0.024), conditional survival beyond 3-month posttransplant was not affected (P = 0.131). Additionally, the cumulative incidence of chronic lung allograft rejection (P = 0.160) and the development of chronic kidney disease (P = 0.757) were not significant between groups. Conclusions: The initiation of CRRT posttransplant may be a useful strategy to preserve cardiac and optimize volume management among critically ill patients.
Long-term Kidney Transplant Survival Across the Globe

Sundaram Hariharan,Natasha Rogers,Maarten Naesens,J. Medina Pestana,Gustavo F. Ferreira,Lucio R. Requião-Moura,Renato D. Foresto,S. Joseph Kim,Katrina Sullivan,Ilkka Helanterä,Valentin Goutaudier,Alexandre Loupy,Vivek B. Kute,Massimo Cardillo,Kazunari Tanabe,Anders Åsberg,Trond Jensen,Beatriz Mahillo,Jong Cheol Jeong,Vathsala Anantharaman,Chris Callaghan,Rommel Ravanan,Derek Manas,Ajay K. Israni,Rajil B. Mehta

DOI: https://doi.org/10.1097/tp.0000000000004977

2024-03-19

Transplantation

Abstract:Background. The outcomes after kidney transplantation (KT), including access, wait time, and other issues around the globe, have been studied. However, issues do vary from one country to another. Methods. We obtained data from several countries from North America, South America, Europe, Asia, and Australia, including the number of patients awaiting KT from 2015, transplant rate per million population (pmp), proportion of living donor and deceased donor (LD/DD) KT, and posttransplant survival. We also sought opinions on key difficulties faced by each of these countries with respect to KT and long-term survival. Results. Variation in access to KT across the globe was noted. Countries with the highest rates of KT pmp included the United States (79%) and Spain (71%). A higher proportion of LD transplants was noted in Japan (93%), India (85%), Singapore (63%), and South Korea (63%). A higher proportion of DD KTs was noted in Spain (90%), Brazil (90%), France (85%), Italy (85%), Finland (85%), Australia–New Zealand (80%), and the United States (77%). The 5-y graft survival for LD was highest in South Korea (95%), Singapore (94%), Italy (93%), Finland (93%), and Japan (93%), whereas for DD, it was South Korea (93%), Italy (88%), Japan (86%), and Singapore (86%). The common issues surrounding KTs are access and a limited number of LDs and DDs. Key issues identified for long-term survival were increasing age of donors and recipients, higher recipient comorbidity, and posttransplant events, such as alloimmune injury to the kidney, infection, cancer, and suboptimal adherence to therapy. Conclusions. A unified approach is necessary to improve issues surrounding KT as the demand continues to increase.

immunology,surgery,transplantation

A study of some new absolute summability methods

Outcomes of Liver–kidney Transplantation in Patients with Primary Hyperoxaluria: an Analysis of the Scientific Registry of Transplant Recipients Database

Survival Outcomes of Lung Transplant Recipients From Donors With Abnormal Kidney Function

Renal Outcomes After Simultaneous Liver‐Kidney Transplantation: Results from the US Multicenter Simultaneous Liver‐Kidney Transplantation Consortium

Kidney After Lung Transplants or Combined Kidney-Lung Transplantation: A Single-Center Retrospective Cohort Study

Temporal Trends and Evolving Outcomes After Simultaneous Liver‐Kidney Transplantation: Results from the US SLKT Consortium

Outcomes of Simultaneous Liver‐Kidney Transplantation Using Kidneys of Deceased Donors With Acute Kidney Injury

The Prevalence, Risk Factors, and Prognosis of Acute Kidney Injury After Lung Transplantation: A Single-Center Cohort Study in China

Lung transplantation in HIV seropositive recipients: An analysis of the UNOS registry

Extended Recipient Criteria in Lung Transplantation: Impact of Pleural Abnormalities on Primary Graft Dysfunction

Kidney Transplantation as a Treatment Option of Chronic Renal Failure Among Lung Transplant Recipients: A Single-Center Experience

Single vs Double Lung Transplantation in Older Adults: A Propensity-Matched Analysis

Performance status at the time of lung retransplant predicts long‐term function

Lung Transplantation In China Between 2015 And 2018

Motion synchronization for multi-cylinder electro-hydraulic system

Outcomes Following Lung Transplant for COVID-19-Related Complications in the US

Outcomes of single vs double lung retransplantation in patients with cystic fibrosis

Longevity Matching for Living Donor Renal Transplantation

Post Liver Transplant Renal Dysfunction-Evaluation, Management and Immunosuppressive Practice

Impact of Postoperative Continuous Renal Replacement Therapy in Lung Transplant Recipients

Long-term Kidney Transplant Survival Across the Globe